MENU
Aim higher

DOAC-STOP

A novel inhibitor to prevent uncontrolled bleedings in anticoagulant users

DOAC-STOP aims to develop PseudoXa, a biological for the instantaneous restoration of blood clotting activity in patients with major bleedings as a result of blood thinners. PseudoXa will be produced and the preclinical efficacy, pharmacokinetics (PK), and toxicity (TOX) of PseudoXa will be determined in vitro and in vivo. The end result will be a completed preclinical study dossier for PseudoXa. After the project, clinical phase development will be initiated.
Acronym: 
DOAC-STOP
Project ID: 
10 859
Ranking: 
104
Cut-off: 
6
Start date: 
01-04-2017
Project Duration: 
24months
Project costs: 
2 674 400.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic